Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors
“At Intellia, we continue to build the broadest and deepest genome editing platform for developing potentially curative treatments for severe diseases,” said Intellia President and Chief Executive Officer
Title: “Special Edition: Expanding Intellia’s Toolbox with Base Editing”
Session: Gene Editing
Date and Time:
- Intellia has developed a therapeutically relevant cytosine deaminase base editor that is equipotent to Cas9 for T cell editing
- The combination of Intellia’s base editor with its proprietary cell engineering process achieved >90% T cell editing efficiency while maintaining translocations at background levels
The presentation can be found here, on the Scientific Publications & Presentations page of Intellia’s website.
Title: “New Era of Genome Editing: In
Session: Nucleic Acid Clinical Programs
Date and Time:
About Intellia Therapeutics
This press release contains “forward-looking statements” of
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to our ability to protect and maintain our intellectual property position; risks related to our relationship with third parties, including our licensors and licensees; risks related to the ability of our licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies’ evaluation of regulatory filings and other information related to our product candidates; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the
Interim Head of
Source: Intellia Therapeutics, Inc.